南风轻轻，中药飘香。 2024年12月19日，习近平总书记在澳门科技大学考察时指出："中医药是中华文明的瑰宝，传承创新发 展中医药是件大事。要把这一祖先留给我们的宝贵财富继承好、发展好、利用好，推动中医药走向世 界。" 2018年10月22日，习近平总书记考察珠海横琴新区粤澳合作中医药科技产业园时强调："中医药学是中 华文明的瑰宝。要深入发掘中医药宝库中的精华，推进产学研一体化，推进中医药产业化、现代化，让 中医药走向世界。" 从一只蜂看中医特色 冰箱里堆满"调料包"，厨房就是"中药房"，一年四季都在吃药膳、煲靓汤、喝凉茶。在广东，几乎人人 都能说出一两个养生药方。木棉花开时节，当地人喜欢捡拾掉落的木棉花朵，洗净晒干之后煲汤，清热 祛湿。广东省卫生健康委副主任、省中医药局局长邱亚洪说："信中医、爱中医、用中医，成为广东人 的生活方式。" 数据来源：广东省中医药管理局等 2024年，广东省医疗卫生机构的中医诊疗量达2.52亿人次，占全省总诊疗量的26.2%。其中，广东省中 医院（广州中医药大学第二附属医院）年服务患者量连续20多年位居全国中医院之首。 蜜蜂一蜇，就能治病？这不是武侠小说里的情节，而是一种古老的中 ...

南风轻轻，中药飘香。 2024年12月19日，习近平总书记在澳门科技大学考察时指出："中医药是中华文明的瑰宝，传承创新发 展中医药是件大事。要把这一祖先留给我们的宝贵财富继承好、发展好、利用好，推动中医药走向世 界。" 2018年10月22日，习近平总书记考察珠海横琴新区粤澳合作中医药科技产业园时强调："中医药学是中 华文明的瑰宝。要深入发掘中医药宝库中的精华，推进产学研一体化，推进中医药产业化、现代化，让 中医药走向世界。" 总书记两次考察，格外关注中医药。"十五五"规划建议提出："推进中医药传承创新，促进中西医结 合。"中医药振兴发展迎来天时、地利、人和的有利时机。 近年来，广东省出台一系列促进中医药传承创新发展的重大举措，全面推进国家中医药综合改革示范区 建设，打造粤港澳大湾区中医药高地，助力中医药扬帆出海，续写岐黄之术的新时代篇章。 一株小草改变世界，一纸经方传承千载，一缕药香穿越古今，一根银针贯通中西。古老的中医药薪火相 传、历久弥新，成为一张亮眼的"中国名片"。 从一只蜂看中医特色 冰箱里堆满"调料包"，厨房就是"中药房"，一年四季都在吃药膳、煲靓汤、喝凉茶。在广东，几乎人人 都能说出一两个养生药 ...

Core Viewpoint - The Guangzhou Pharmaceutical Group is entering a new phase of brand development with the establishment of the Brand Strategy Committee, focusing on a comprehensive brand strategy for the next five years [1]. Group 1: Brand Strategy and Management - The brand strategy framework is centered around "1+6," where "1" represents a unified brand strategy plan and "6" signifies six key strategic initiatives [1]. - The establishment of the Brand Strategy Committee marks a significant step in the company's brand construction efforts [1]. Group 2: Business Performance and Growth - The company aims to double its business performance, with key strategies including regional expansion and internationalization of technology innovation [4]. - The acquisition of Caishantang is highlighted as a successful case of regional expansion, achieving a fourfold revenue increase after expanding its market presence beyond Fujian Province [4]. Group 3: Scientific Research and Internationalization - The company emphasizes the importance of scientific research to validate the effectiveness of traditional Chinese medicine, aiming for international collaboration with research institutions in North America and Europe [5][6]. - Recent achievements include the publication of a product in a top international journal and the recognition of another product in Russia, showcasing the potential for traditional medicine to be integrated into global healthcare solutions [6]. Group 4: Strategic Partnerships and Capital Operations - Under the leadership of Li Xiaojun, the company has accelerated its capital operations and formed strategic partnerships, including a collaboration with Huawei to enhance its international strategy [7]. - The company has made significant investments in innovative drugs and high-end medical devices, with plans for substantial R&D and investment in the coming years [7]. Group 5: Policy Recommendations and Industry Development - Li Xiaojun has proposed measures to support the biopharmaceutical industry, including establishing a systematic error-correction mechanism and creating a global talent network [8]. - Recommendations also include developing a collaborative response mechanism for international trademark disputes to support companies venturing abroad [8].

Core Viewpoint - Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited reported a slight increase in revenue but a decline in total profit for the first half of 2025, indicating challenges in the industry and competitive pressures [14][12]. Financial Summary - The company achieved a revenue of RMB 41.83 billion, a year-on-year increase of 1.93% [14]. - Total profit amounted to RMB 3.09 billion, reflecting a decrease of 4.30% compared to the previous year [14]. - The net profit attributable to shareholders was RMB 2.45 billion, with a decrease in cash flow from operating activities by 66.79% to RMB -3.40 billion [14][7]. Company Overview - The company focuses on the pharmaceutical and health industry, engaging in the research, development, manufacturing, and sales of traditional Chinese medicine, chemical raw materials, and health products [8][11]. - It operates 27 pharmaceutical manufacturing enterprises and institutions, including 3 branches and 22 directly controlled subsidiaries [8][9]. Industry Position - The company is one of the largest pharmaceutical groups in China, with a comprehensive layout in the biopharmaceutical health industry [13]. - It holds a leading position in traditional Chinese medicine, chemical generic drugs, and health products, with several core products ranking first in their respective market segments [13][21]. Business Segments - The pharmaceutical segment includes the production and sales of traditional Chinese medicine and chemical drugs, while the health segment focuses on beverages and health products, notably the Wanglaoji herbal tea [10][11]. - The commercial segment is involved in the wholesale and retail of pharmaceutical products and medical devices, with Guangzhou Medicine being a key player in the South China market [10][11]. Growth Strategies - The company is enhancing its pharmaceutical manufacturing capabilities and expanding its market presence through innovation and strategic partnerships [15][18]. - It aims to strengthen its international market presence by registering products overseas and forming strategic collaborations with international companies [17][18]. Research and Development - The company has established a robust research and development framework, with numerous ongoing projects in traditional Chinese medicine and innovative drug development [21]. - It has received multiple awards for its research achievements and continues to invest in technological advancements to enhance its product offerings [21].

Group 1 - The 2025 Fortune Global 500 list reveals that the total revenue of the listed companies is approximately $41.7 trillion, which exceeds one-third of the global GDP, marking a growth of about 1.8% compared to the previous year [1] - A total of 130 Chinese companies made the list, ranking second after the United States, with a combined revenue of approximately $10.7 trillion for 2024 [1] - High-tech sectors are highlighted as the forefront of global technological development, with significant performance improvements among listed high-tech companies [1] Group 2 - Guangzhou Pharmaceutical Holdings is the only Chinese company included in the pharmaceutical sector of the 2025 Fortune Global 500 list, having been listed for three consecutive years [2] - The pharmaceutical sector features eight American companies and seven European companies, while China has three companies listed [5] Group 3 - Chinese pharmaceutical companies, including Guangzhou Pharmaceutical, have made significant advancements in research and development, with over 200 ongoing projects in various drug categories [6] - The Chinese pharmaceutical industry is transitioning towards innovative drugs and biopharmaceuticals, with leading companies driving this transformation through independent research and strategic mergers [8] Group 4 - Digital transformation is essential for Chinese pharmaceutical companies, with initiatives underway to enhance competitiveness and quality management across the entire industry chain by 2027 [9] - Guangzhou Pharmaceutical is implementing a comprehensive digital strategy, including smart production and logistics systems, and has partnered with Huawei for digital transformation [9] Group 5 - The internationalization of traditional Chinese medicine is accelerating, with Chinese companies expanding their global presence through product development and market outreach [11] - Guangzhou Pharmaceutical's products have reached over 29 countries and regions, and the company is actively pursuing strategic partnerships to enhance its international footprint [11] Group 6 - Capital operations are becoming a powerful lever for resource integration and industry upgrades in the pharmaceutical sector [13] - Guangzhou Pharmaceutical is transitioning to a modern model of "industry incubation + capital operation," with recent acquisitions and the establishment of investment funds to support growth in the biopharmaceutical sector [14] Group 7 - The Fortune Global 500 list serves as a motivational signal for Chinese companies, indicating the rising position of Chinese innovative drugs in the global pharmaceutical industry [15] - The Chinese pharmaceutical sector is experiencing unprecedented vitality, marking the beginning of a new era in pharmaceutical innovation [15]

据广药集团介绍，目前集团已建成各级科研平台超100家，国家级科研机构15家，高新技术企业超20 家，国家级及省级专精特新"小巨人"企业近20家；获得国家科学技术进步奖3项、国家技术发明奖1项， 有效发明专利授权超800件，实用新型专利超200件，外观专利超500件，获得中国专利优秀奖超30项； 拥有疫苗类生物药、抗体类生物药、化学药创新药、中药新药等在研项目200余项。 其中，广药集团中药制药过程技术与新药创制国家工程研究中心是广东省唯一一家中药领域纳入新序列 管理的国家工程研究中心。"国家犬类实验动物资源库"入选国家科技资源共享服务平台（与国家实验室 同级），有效解决我国"卡脖子"式实验用比格犬的战略性资源问题。公司旗下采芝林药业牵头的"广东 创新中药制剂转化中试平台"入选工信部首批中试平台。 7月29日，2025年《财富》世界500强榜单发布，广药集团连续五年上榜，今年位居第459位，同时连续 三年入选制药分行业榜单，位居第14位，仅次于葛兰素史克集团，是制药分行业榜单中唯一的中国企 业。在7月22日发布的2025年《财富》中国500强排行榜中，广药集团上榜第115名，位居医药类企业前 三。 在数字化方面 ...